David Keeling

First‐in‐Human Study With the Inhaled TLR9 Oligonucleotide Agonist AZD1419 Results in Interferon Responses in the Lung, and Is Safe and Well‐Tolerated

Sam Jackson, Albert F. Candia, Stephen Delaney et al. · Clinical Pharmacology & Therapeutics · 2017 · 30 citations

Life Sciences, Immunology, Pharmacology +15

A Phase 2a, Double-Blind, Placebo-controlled Randomized Trial of Inhaled TLR9 Agonist AZD1419 in Asthma

Ioannis Psallidas, Vibeke Backer, Piotr Kuna et al. · American Journal of Respiratory and Critical Care Medicine · 2020 · 27 citations

Life Sciences, Immunology, Pharmacology +14

Tolerability in man following inhalation dosing of the selective TLR7 agonist, AZD8848

Stephen Delaney, Mark Biffen, Justine Maltby et al. · BMJ Open Respiratory Research · 2016 · 21 citations · Full text

Life Sciences, Immunology, Pharmacology +16

Pharmacokinetics, pharmacodynamics and safety of the inverse retinoic acid‐related orphan receptor γ agonist AZD0284

Sara Asimus, Robert S. Palmer, Muna Albayaty et al. · British Journal of Clinical Pharmacology · 2020 · 17 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +9

Temporal cytokine and lymphoid responses to an inhaled TLR7 antedrug agonist in the cynomolgus monkey demonstrates potential safety and tolerability of this approach

John Bell, Mike Dymond, Mark Biffen et al. · Toxicology and Applied Pharmacology · 2017 · 12 citations

Life Sciences, Immunology, Pharmacology +17